Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Du Bois, C. Albera, W. Bradford, U. Costabel, T. King, S. Sahn, J. Szwarcberg, D. Valeyre, P. Noble (Denver, Brisbane, San Francisco, Charleston, Durham, United States Of America; Turin, Italy; Essen, Germany; Paris, France). Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety. Eur Respir J 2009; 34: Suppl. 53, 2823

Member's Comments

No comment yet.

Related content which might interest you: Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 A prosprective study on the safety, tolerability and efficacy of pirfinidone in the treatment of idiopathic pulmonary fibrosis and fibrotic NSIP Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017